Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Accounts Payables: 2020-2024

Historic Accounts Payables for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $5.5 million.

  • SAB Biotherapeutics' Accounts Payables fell 0.43% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 0.43%. This contributed to the annual value of $5.5 million for FY2024, which is 18.22% down from last year.
  • SAB Biotherapeutics' Accounts Payables amounted to $5.5 million in FY2024, which was down 18.22% from $6.7 million recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Accounts Payables registered a high of $12.5 million during FY2021, and its lowest value of $5.5 million during FY2024.
  • In the last 3 years, SAB Biotherapeutics' Accounts Payables had a median value of $6.7 million in 2023 and averaged $7.4 million.
  • In the last 5 years, SAB Biotherapeutics' Accounts Payables skyrocketed by 68.72% in 2021 and then crashed by 32.52% in 2023.
  • SAB Biotherapeutics' Accounts Payables (Yearly) stood at $7.4 million in 2020, then soared by 68.72% to $12.5 million in 2021, then dropped by 20.38% to $9.9 million in 2022, then crashed by 32.52% to $6.7 million in 2023, then dropped by 18.22% to $5.5 million in 2024.